Monitoring monoclonal antibody delivery in oncology: the example of bevacizumab.

Developing therapeutic monoclonal antibodies paves the way for new strategies in oncology using targeted therapy which should improve specificity. However, due to a lack of biomarkers, a personalized therapy scheme cannot always be applied with monoclonal antibodies. As a consequence, the efficacy o...

Full description

Bibliographic Details
Main Authors: Guillaume Nugue, Marie Bidart, Marie Arlotto, Mireille Mousseau, François Berger, Laurent Pelletier
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2013-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3741214?pdf=render